...
首页> 外文期刊>癌と化学療法 >An inadvertent contraindicated combined use of newly prescribed TS-1 and unused doxifluridine
【24h】

An inadvertent contraindicated combined use of newly prescribed TS-1 and unused doxifluridine

机译:一种无意的禁忌结合新规定的TS-1和未使用的Doxifluridine

获取原文
获取原文并翻译 | 示例

摘要

A 77-year-old male patient who had been receiving doxifluridine (5'-DFUR) for about a year after surgery for rectal cancer, was newly prescribed TS-1, because tumor markers were elevated and abdominal ultrasonography documented liver metastasis. However, the patient took TS-1 concomitantly with 5'-DFUR, which is contraindicated to TS-1, and experienced a severe drug interaction. This inadvertent drug interaction was caused by a combination of the newly prescribed drug and the unused drug remaining at the patient's home. This type of medication error has not been reported previously. Health professionals should be aware of such drug interactions which may be caused by newly prescribed drugs plus unused drugs remaining in the patient's home. Furthermore, health professionals should instruct patients on the nature of drug interactions as well as explaining their diagnosis and treatment. Although the severity of such drug interaction may vary, health professionals must be alerted to such incidents, which could happen frequently.
机译:一位77岁的男性患者在直肠癌手术后接受Doxifluridine(5'-Dfur)的一年,是新规定的TS-1,因为肿瘤标志物升高,腹部超声检查记录肝转移。然而,患者伴随着5'-DFUR的TS-1,这与TS-1禁用,并且经历了严重的药物相互作用。这种无意的药物相互作用是由新规定的药物和留在患者家中的未使用药物的组合引起的。此类药物错误尚未报告。卫生专业人士应该了解此类药物相互作用,可能是由新规定的药物加上患者家中剩余的未使用药物造成的药物相互作用。此外,卫生专业人员应指导患者对药物相互作用的性质以及解释其诊断和治疗。虽然这种药物互动的严重程度可能会有所不同,但必须警告卫生专业人员此类事件,这可能经常发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号